External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Aurobindo Pharma Limited (ARBP) is an integrated global pharmaceutical company headquartered in Hyderabad, India.</li><li>The company is engaged in the development, manufacturing, and commercialization of a wide range of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide, spanning across more than 150 countries.</li><li>With a presence in over 25 manufacturing and packaging facilities, Aurobindo Pharma holds approvals from leading regulatory agencies including the USFDA, MHRA, EDQM, PMDA, WHO, Health Canada, MCC, and ANVISA. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aurobindo Pharma Limited (ARBP) is an integrated global pharmaceutical company headquartered in Hyderabad, India.The company is engaged in the development, manufacturing, and commercialization of a wide range of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide, spanning across more than 150 countries.With a presence in over 25 manufacturing and packaging facilities, Aurobindo Pharma holds approvals from leading regulatory agencies including the USFDA, MHRA, EDQM, PMDA, WHO, Health Canada, MCC, and ANVISA. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pick of the Week - Aurobindo Pharma Ltd - 04 MAR 2024

Equity Analyst, Event-driven, Quiddity Advisors

Janaghan Jeyakumar, CFA

Equity Analyst, Event-driven

Quiddity Advisors

Pan-Asia Catalysts/Events

Event-Driven

<ul>
<li>In this insight, we take a look at the Potential ADDs/DELs for the BSE SENSEX, 100, and 200 Indices in the June 2024 index rebal event.</li>
<li>
<a href="https://www.smartkarma.com/entities/wipro-ltd" target="_blank" data-smartkarma-citation="entities:15360:1" rel="noopener">Wipro Ltd (WPRO IN)</a>'s deletion from Sensex is imminent but there are question marks over the top replacement names as this involves some subjectivity.  </li>
<li>For BSE 100, <a href="https://www.smartkarma.com/entities/jio-financial-services-limited" target="_blank" data-smartkarma-citation="entities:40042:1" rel="noopener">Jio Financial Services (JIOFIN IN)</a> is a new potential ADD and that has caused major changes to the index change expectations I had previously.</li>
</ul>


In this insight, we take a look at the Potential ADDs/DELs for the BSE SENSEX, 100, and 200 Indices in the June 2024 index rebal event.

Wipro Ltd (WPRO IN)'s deletion from Sensex is imminent but there are question marks over the top replacement names as this involves some subjectivity.  
For BSE 100, Jio Financial Services (JIOFIN IN) is a new potential ADD and that has caused major changes to the index change expectations I had previously.


Quiddity Leaderboard BSE/​​​​SENSEX Jun 24: Jio Financial Addition Creates New Possibilities

<ul><li>Aurobindo Pharma's PAT stood above our estimates by 14%.</li><li>The company’s consolidated revenue grew by 25.8% YoY and gross margins improved by 122bps QoQ.</li><li>EBITDA margins improved by 222bps QoQ. The US revenue at $409 Mn was up 7.1% QoQ. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aurobindo Pharma's PAT stood above our estimates by 14%.The company’s consolidated revenue grew by 25.8% YoY and gross margins improved by 122bps QoQ.EBITDA margins improved by 222bps QoQ. The US revenue at $409 Mn was up 7.1% QoQ. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aurobindo Pharma Ltd - Several Growth Levers in Place to Drive Topline

<ul><li>Aurobindo Pharma's PAT stood above our estimates by 3.7%.</li><li>The company’s consolidated revenue grew by 9.9% YoY and gross margins improved by 24bps YoY.</li><li>EBITDA margins improved by 179bps YoY. The US revenue at $402 Mn was up 8.6% QoQ. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aurobindo Pharma's PAT stood above our estimates by 3.7%.The company’s consolidated revenue grew by 9.9% YoY and gross margins improved by 24bps YoY.EBITDA margins improved by 179bps YoY. The US revenue at $402 Mn was up 8.6% QoQ. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aurobindo Pharma Ltd - Number of Growth Levers in Place to Drive Topline

<ul><li>Aurobindo Pharma' reported PAT missed estimates by 5%. Consol. Revenue grew by 11.4% YoY, Gross margins decreased by 183 bps YoY and EBITDA margins decreased by 130 bps YoY.</li><li>US revenue USD$ 370 Mn, +2% YoY, however injectable business in the US reported flat growth YoY despite good numbers of injectable approvals in last year.</li><li>Oral and OTC business has driven growth in the US by 6% and 17% YoY respectively.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aurobindo Pharma' reported PAT missed estimates by 5%. Consol. Revenue grew by 11.4% YoY, Gross margins decreased by 183 bps YoY and EBITDA margins decreased by 130 bps YoY.US revenue USD$ 370 Mn, +2% YoY, however injectable business in the US reported flat growth YoY despite good numbers of injectable approvals in last year.Oral and OTC business has driven growth in the US by 6% and 17% YoY respectively.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aurobindo Pharma Ltd - Number of Livers to Drive Topline

India

Aurobindo Pharma Limited manufactures and markets oral and sterile antibiotics, antibacterials, anti-ulcerants and other generic basic drugs. Products include semi-synthetic penicillin drugs like ampicillin and amoxycillinas well as antibiotics, which include cloxacillin and dicloxacillin. The Company also manufactures formulations like astemizole, domeperidone and omeprazole.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aurobindo Pharma (ARBP IN)

Pick of the Week - Aurobindo Pharma Ltd - 04 MAR 2024

The company is engaged in the development, manufacturing, and commercialization of a wide range of generic pharmaceuticals, branded specialty...

Axis Direct

Quiddity Leaderboard BSE/SENSEX Jun 24: Jio Financial Addition Creates New Possibilities

The reference period for the BSE/SENSEX June 2024 ended on 30th April 2024. The index expectations discussed in this insight are our final...

Janaghan Jeyakumar, CFA

Aurobindo Pharma Ltd - Several Growth Levers in Place to Drive Topline

Aurobindo Pharma's PAT stood above our estimates by 14%. The company’s consolidated revenue grew by 25.8% YoY and gross margins improved by 122bps...

Axis Direct

Aurobindo Pharma Ltd - Number of Growth Levers in Place to Drive Topline

Aurobindo Pharma's PAT stood above our estimates by 3.7%. The company’s consolidated revenue grew by 9.9% YoY and gross margins improved by 24bps YoY.

Axis Direct

Aurobindo Pharma Ltd - Number of Livers to Drive Topline

Aurobindo Pharma' reported PAT missed estimates by 5%. Consol. Revenue grew by 11.4% YoY, Gross margins decreased by 183 bps YoY and EBITDA margins...

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pick of the Week - Aurobindo Pharma Ltd - 04 MAR 2024

The company is engaged in the development, manufacturing, and commercialization of a wide range of generic pharmaceuticals, branded specialty...

Axis Direct

Quiddity Leaderboard BSE/​​​​SENSEX Jun 24: Jio Financial Addition Creates New Possibilities

The reference period for the BSE/SENSEX June 2024 ended on 30th April 2024. The index expectations discussed in this insight are our final...

Janaghan Jeyakumar, CFA

Aurobindo Pharma Ltd - Several Growth Levers in Place to Drive Topline

Aurobindo Pharma's PAT stood above our estimates by 14%. The company’s consolidated revenue grew by 25.8% YoY and gross margins improved by 122bps...

Axis Direct

Aurobindo Pharma Ltd - Number of Growth Levers in Place to Drive Topline

Aurobindo Pharma's PAT stood above our estimates by 3.7%. The company’s consolidated revenue grew by 9.9% YoY and gross margins improved by 24bps YoY.

Axis Direct

Aurobindo Pharma Ltd - Number of Livers to Drive Topline

Aurobindo Pharma' reported PAT missed estimates by 5%. Consol. Revenue grew by 11.4% YoY, Gross margins decreased by 183 bps YoY and EBITDA margins...

Axis Direct

Quiddity Leaderboard BSE/SENSEX Jun 24: Jio Financial Addition Creates New Possibilities